---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018794"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:35:18.440509+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax Q1 net loss $41.1M; on track for two pivotal readouts and NDA/BLA filings in 2023

## Summary
- Net loss of $41.1M ($0.59/sh) vs $37.2M ($0.63/sh) YoY; cash $449M as of Mar 31, 2023.
- Topline data from AGAVE-201 (axatilimab in cGVHD) expected mid-2023; BLA filing by end of 2023.
- Topline data from AUGMENT-101 (revumenib in KMT2Ar acute leukemia) expected Q3 2023; NDA filing by end of 2023.
- Alexander Nolte resigned as VP, CAO; CFO Keith Goldan appointed as Principal Accounting Officer.
- Full-year 2023 R&D expense guidance reaffirmed at $160-175M; total op ex $225-240M.

## SEC filing metadata
- accession: 0000950170-23-018794
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/sndx-20230505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018794
- JSON: https://secwatch.observer/filing/0000950170-23-018794.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018794.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, Syndax Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm
- Executive change
  Alexander Nolte resigned as Vice President, Chief Accounting Officer at Syndax Pharmaceuticals Inc.
  - Action: resigned
  - Role: Vice President, Chief Accounting Officer
  source text: Effective May 5, 2023, Alexander Nolte resigned from his positions as the Company’s Vice President, Chief Accounting Officer and its Principal Accounting Officer, in order to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm
- Executive change
  Keith A. Goldan was appointed as Principal Accounting Officer at Syndax Pharmaceuticals Inc.
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: The Company has appointed Keith A. Goldan, the Company’s Chief Financial Officer, Treasurer and its Principal Financial Officer, as its Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.